CFTR Therapeutics Normalize Cerebral Perfusion Deficits in Mouse Models of Heart Failure and Subarachnoid Hemorrhage

Darcy Lidington, Jessica C. Fares, Franziska E. Uhl, Danny D. Dinh, Jeffrey T. Kroetsch, Meghan Sauvé, Firhan A. Malik, Frank Matthes, Lotte Vanherle, Arman Adel, Abdul Momen, Hangjun Zhang, Roozbeh Aschar-Sobbi, Warren D. Foltz, Hoyee Wan, Manabu Sumiyoshi, R. Loch Macdonald, Mansoor Husain, Peter H. Backx, Scott P. HeximerAnja Meissner, Steffen Sebastian Bolz

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskriftPeer review

Sammanfattning

Heart failure (HF) and subarachnoid hemorrhage (SAH) chronically reduce cerebral perfusion, which negatively affects clinical outcome. This work demonstrates a strong relationship between cerebral artery cystic fibrosis transmembrane conductance regulator (CFTR) expression and altered cerebrovascular reactivity in HF and SAH. In HF and SAH, CFTR corrector compounds (C18 or lumacaftor) normalize pathological alterations in cerebral artery CFTR expression, vascular reactivity, and cerebral perfusion, without affecting systemic hemodynamic parameters. This normalization correlates with reduced neuronal injury. Therefore, CFTR therapeutics have emerged as valuable clinical tools to manage cerebrovascular dysfunction, impaired cerebral perfusion, and neuronal injury.

Originalspråkengelska
Sidor (från-till)940-958
Antal sidor19
TidskriftJACC: Basic to Translational Science
Volym4
Nummer8
DOI
StatusPublished - 2019

Ämnesklassifikation (UKÄ)

  • Kardiologi

Fingeravtryck

Utforska forskningsämnen för ”CFTR Therapeutics Normalize Cerebral Perfusion Deficits in Mouse Models of Heart Failure and Subarachnoid Hemorrhage”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här